Concepedia

Xiaolun Wang

XW

Statistics

Publications

21

Citations

2.1K

H-Index

16

Active since

1999

Affiliations

Mirati Therapeutics (United States)(Current)

Pfizer (United States)

Takeda (United States)

Columbia University

Pearl River Community College

Xiaolun Wang is an author at Mirati Therapeutics (United States) specializing in medicinal chemistry, drug discovery, and pharmacology.

ORCID

Publications per year

1999–2024

21

Publications

21

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS <sup>G12D</sup> Inhibitor

Xiaolun Wang, Shelley Allen, James F. Blake et al. · Journal of Medicinal Chemistry · 2021 · 708 citations · Full text

, , +14

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Jill Hallin, Vickie Bowcut, Andrew Calinisan et al. · Nature Medicine · 2022 · 507 citations

, , +9

Strained Silacycles in Organic Synthesis:  A New Reagent for the Enantioselective Allylation of Aldehydes

James W. A. Kinnaird, Pui Yee Ng, Katsumi Kubota et al. · Journal of the American Chemical Society · 2002 · 178 citations

, , +10

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i> -Deleted Cancers

Christopher R. Smith, Ruth Aranda, Thomas P. Bobinski et al. · Journal of Medicinal Chemistry · 2022 · 151 citations · Full text

, , +15

Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction

John M. Ketcham, Jacob R. Haling, Shilpi Khare et al. · Journal of Medicinal Chemistry · 2022 · 94 citations · Full text

, , +11

1–5 of 21